Dr. Lal Pathlabs Q4 Review - Industry Leading Performance Continues: ICICI Securities
A healthcare worker uses a pipette to process Covid-19 test samples in a laboratory (Photographer T. Narayan/Bloomberg)

Dr. Lal Pathlabs Q4 Review - Industry Leading Performance Continues: ICICI Securities

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Securities Report

Dr. Lal Pathlabs Ltd.'s Q4 FY21 performance was above estimate with strong growth recovery in the ex-Covid-19 business and higher revenue from Covid-19 related tests.

Though, Covid-19 and allied tests contribution dropped to 11.2% of sales (21.6% in Q3 FY21).

Base business revenues grew 28.6% YoY. Overall, revenue grew 42.9%, Ebitda margin was up 930 basis points YoY to 28.3% and adjusted profit after tax was up 157% to Rs 834 million.

The base business has seen good recovery QoQ since Q2 FY21 and we expect healthy growth in coming quarters to continue.

The second wave of Covid-19 may have some impact on base business in Q1 FY22, however the longer term outlook remains strong.

Click on the attachment to read the full report:

ICICI Securities Dr Lal Q4FY21 Results Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.